NIH awards $12.1M for preclinical research, spanning 8 years with full and open competition
Contract Overview
Contract Amount: $12,139,180 ($12.1M)
Contractor: Washington University, the
Awarding Agency: Department of Health and Human Services
Start Date: 2004-05-15
End Date: 2012-11-14
Contract Duration: 3,105 days
Daily Burn Rate: $3.9K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 5
Pricing Type: COST NO FEE
Sector: R&D
Official Description: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ASSAYS
Place of Performance
Location: SAINT LOUIS, SAINT LOUIS County, MISSOURI, 63130
State: Missouri Government Spending
Plain-Language Summary
Department of Health and Human Services obligated $12.1 million to WASHINGTON UNIVERSITY, THE for work described as: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ASSAYS Key points: 1. Significant investment in early-stage R&D, potentially leading to future medical breakthroughs. 2. Competition was full and open, suggesting a robust market for these research services. 3. Long contract duration (8 years) may indicate complex, multi-phase research. 4. Focus on physical, engineering, and life sciences aligns with NIH's mission.
Value Assessment
Rating: fair
The contract value of $12.1M over 8 years averages $1.5M annually. Without specific benchmarks for preclinical efficacy assays, it's difficult to definitively assess pricing, but it appears moderate for extensive research.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
Full and open competition was utilized, indicating multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and ensures the government receives the best value.
Taxpayer Impact: The competitive nature of the award suggests taxpayer funds were likely used efficiently to secure necessary research services.
Public Impact
Supports critical early-stage medical research with potential long-term health benefits. Funds academic institutions, contributing to scientific advancement and knowledge creation. The research could lead to new diagnostic tools or therapeutic targets.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Long contract duration could lead to scope creep or changing research needs.
- Lack of specific performance metrics makes assessing true value challenging.
Positive Signals
- Full and open competition ensures broad market access and potential for innovation.
- Investment in R&D aligns with national health priorities.
Sector Analysis
This contract falls under Research and Development in the Physical, Engineering, and Life Sciences. Spending in this sector is crucial for innovation but can be highly variable and long-term, making direct spending benchmarks difficult.
Small Business Impact
The data does not indicate if small businesses participated in or benefited from this contract. Further analysis would be needed to determine small business involvement.
Oversight & Accountability
The contract was awarded by NIH, a reputable agency with established oversight processes. The long duration warrants monitoring for continued relevance and effective use of funds.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences
- Department of Health and Human Services Contracting
- National Institutes of Health Programs
Risk Flags
- Long contract duration (8 years)
- Lack of specific performance metrics
- Potential for research to yield inconclusive results
- High cost associated with extensive preclinical research
Tags
research-and-development-in-the-physical, department-of-health-and-human-services, mo, definitive-contract, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $12.1 million to WASHINGTON UNIVERSITY, THE. PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ASSAYS
Who is the contractor on this award?
The obligated recipient is WASHINGTON UNIVERSITY, THE.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (National Institutes of Health).
What is the total obligated amount?
The obligated amount is $12.1 million.
What is the period of performance?
Start: 2004-05-15. End: 2012-11-14.
What specific preclinical efficacy and biomarker assays were performed, and how do they align with current scientific needs?
The contract details are limited, but the focus on preclinical efficacy and intermediate biomarker assays suggests research into the effectiveness and biological impact of potential treatments or interventions before human trials. This aligns with the critical need to validate scientific hypotheses and identify promising candidates for further development in various disease areas.
What are the key performance indicators (KPIs) for this contract, and how was success measured over its 8-year duration?
Specific KPIs are not detailed in the provided data. Typically, for R&D contracts, success is measured by the achievement of research milestones, publication of findings, generation of data supporting further development, and the identification of viable biomarkers or efficacy signals. The long duration implies a phased approach to measurement.
How does the $12.1M award compare to similar preclinical research contracts awarded by NIH or other agencies?
Benchmarking this $12.1M award requires comparing it to contracts for similar preclinical efficacy and biomarker assay research, considering factors like research scope, duration, and institution. Without access to a comprehensive database of comparable contracts, a precise comparison is difficult. However, the annual average of $1.5M suggests a substantial, multi-year research effort.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences
Product/Service Code: RESEARCH AND DEVELOPMENT › OTHER RESEARCH/DEVELOPMENT
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation ID: N01CN25007
Offers Received: 5
Pricing Type: COST NO FEE (S)
Contractor Details
Address: ONE BROOKINGS DRIVE, CAMPUS BOX 105, SAINT LOUIS, MO, 63130
Business Categories: Category Business, Educational Institution, Higher Education, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $42,161,361
Exercised Options: $42,161,361
Current Obligation: $12,139,180
Contract Characteristics
Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED
Timeline
Start Date: 2004-05-15
Current End Date: 2012-11-14
Potential End Date: 2012-11-14 00:00:00
Last Modified: 2024-11-23
More Contracts from Washington University, the
- Biomedical (basic) — $31.7M (Department of Health and Human Services)
- TAS::75 0872::TAS Washington University Cardiovascular Program of Excellence in Nanotechnology — $18.8M (Department of Health and Human Services)
- Mentored Dissemination and Implementation Training (medit) Program for TWO VA Fellows — $55.0K (Department of Veterans Affairs)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →